What top creators are saying about LifeMD, Inc.(LFMD)

Identified as a peer and competitor to Hims in the direct-to-consumer healthcare sector with room for competition.

Better play than HIMS due to pharmacy ownership; high upside tied to the July 23rd FDA meeting regarding compound peptides.

The market trend of patients switching from expensive GLP-1s to affordable oral medications is seen as a positive indicator for the company as it offers similar diversified weight loss programs.

Cited as an 'under-followed, unknown hyper-growth stock' that is less correlated to the broader market, offering portfolio protection during crashes. It was down only 3% in a recent sell-off.

Used as an example to highlight the cash flow problems of dealing with insurance; the company ships products but may not get paid if insurance denies a claim, forcing it to absorb the loss.

A deep-value play in digital health, considered 'way too cheap' and valued at about four times cheaper than its competitor HIMS. The investment thesis is based on its low valuation being too cheap to ignore, despite slower execution.

The speaker is bearish on LifeMD when compared to HIMS, criticizing its strategy of working within the traditional insurance system, which is believed to make it less agile and slower to innovate.

Mentioned as an example of a '#2 player' or 'challenger' stock to Hims & Hers within the investment theme of backing challengers.

Highlighted as an example of a small-cap stock that has been pushed down too far in an indiscriminate market sell-off and is now considered 'too cheap'.

Presented as a significantly undervalued value play compared to its peer HIMS, being 'three times cheaper' on a price-to-growth basis. The company is cash flow positive, has no debt, high gross margins, and a key differentiator in its strategy of working with insurance for branded GLP-1s.

The stock has seen a massive 70% drawdown and is considered 'unprecedentedly cheap' with a valuation metric of 0.029, presenting a deep value opportunity for investors who believe in its subscription model.

Mentioned as an example of a small-cap growth stock that has experienced an even more severe drop than MicroStrategy during the market sell-off.

Considered a deeply undervalued, high-growth 'baby HIMS' trading at very low multiples. A recent price drop due to a minor, misunderstood accounting change is seen as a significant buying opportunity.

The sale of its WorkSimply subsidiary is a major positive catalyst, removing AI risk and simplifying the business story. The company is now a 'pure-play' telehealth provider with a visible growth rate projected around 32% and is considered significantly undervalued compared to competitor HIMS.

Mentioned as a competitor whose earnings commentary suggests a sector-wide issue in the Erectile Dysfunction market has been fixed, which is a positive leading indicator for HIMS.

Highlighted as a company sold off despite having 'nothing to do with' tariff news, representing a potential buying opportunity in a company unfairly punished by market panic.

An under-the-radar, smaller alternative to HIMS. Its growth story is complicated by a flat-growth division currently for sale; a sale could unlock a higher perceived growth rate for the core business.

Considered a 'dirt cheap' competitor to Hims, but viewed as a lower quality company by the speaker. It represents a relative value play in the telehealth sector.

Believed to be the 'better deal' compared to HIMS because it has a lower risk profile (no GLP-1 lawsuit risk) yet its stock has dropped in tandem, presenting a more attractive risk/reward.

Considered strongly bullish due to its attractive valuation compared to competitor HIMS, being 'almost three times as cheap'. It is also seen as a 'safer play' with lower lawsuit risk as it sells branded drugs from partners instead of compounding them. The company has multiple growth catalysts, including new women's health and mental health programs.

The speaker is very bullish, calling the -44% stock drop a 'clear overreaction' and viewing the stock as 'heavily undervalued' due to the market ignoring its diversified strengths beyond GLP-1s.

The stock is considered short-term bearish after a -32% drop following a significant cut in full-year revenue guidance. The company faces major challenges with its insurance-based GLP-1 model and high customer acquisition costs in its ED business.

While noted as being 'technically a little cheaper' than HIMS, the host believes HIMS now has a superior growth outlook due to the Canadian opportunity, making LFMD a less compelling investment in comparison.

Acknowledged as a competitor to Hims, but viewed as an inferior 'edge case' investment because it is not an all-in-one platform like Hims.

Trades at the same cheap valuation metric as HIMS and has had an 'outstanding run', but the speaker implies a strong preference for HIMS, making LifeMD a secondary choice.